



US008591898B2

(12) **United States Patent**  
**Mills et al.**

(10) **Patent No.:** **US 8,591,898 B2**  
(45) **Date of Patent:** **Nov. 26, 2013**

(54) **TREATMENT OF INTERSTITIAL CYSTITIS**

OTHER PUBLICATIONS

(75) Inventors: **Ian William Mills**, Sandwich (GB);  
**Stephen Charles Phillips**, Sandwich  
(GB); **Arnon Rosenthal**, Woodside, CA  
(US); **David Peter Scholfield**, Sandwich  
(GB); **David Louis Shelton**, Oakland,  
CA (US)

Rudikoff et al. (1982). Single amino acid substitution altering anti-  
gen-binding specificity. Proc. Natl. Acad. Sci. USA. 79:1979-1983.\*  
Dimitrakov et al, Journal of Urology, vol. 171, No. 4 Supplement,  
2004, p. 95.  
Hefti et al., Trends in Pharmacological Sciences, vol. 27, No. 2, 2006,  
pp. 85-91.  
Lowe et al., British Journal of Urology, vol. 79, No. 4, 1997, pp.  
572-577.

(73) Assignee: **Pfizer Limited**, Sandwich, Kent (GB)

Miller et al., Urology, vol. 59, No. 4, 2002, pp. 603-608.  
Sevcik et al., Pain, vol. 115, No. 1-2, 2005, pp. 128-141.  
Shelton et al., Pain, vol. 116, No. 1-2, 2005, pp. 8-16.  
International Search Report, PCT/IB2008/055383, mailed Jun. 15,  
2009.

(\* ) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 266 days.

Wakabayashi, et al., "Low-affinity nerve growth factor receptor  
immunoreactivity in the human urinary bladder," *Neuroscience let-  
ters*, 1995, 9-12, vol. 186, No. 1.

(21) Appl. No.: **12/747,262**

(22) PCT Filed: **Dec. 17, 2008**

Dmitrieva, et al., "The role of nerve growth factor in a model of  
visceral inflammation," *Neuroscience*, 1997, 449-459, vol. 78, No. 2.  
Faydaci, et al., "Role of nerve growth factor receptor on bladder  
outlet obstruction," *Turk Uroloji Dergisi (Turkish Journal of Urol-  
ogy)*, 2004, 72-79. Abstract.

(86) PCT No.: **PCT/IB2008/055383**

§ 371 (c)(1),  
(2), (4) Date: **Jun. 10, 2010**

Goins, et al., "Herpes simplex virus mediated nerve growth factor  
expression in bladder and afferent neurons: potential treatment for  
diabetic bladder dysfunction," *J. Urol.*, 2001, 1748-1754, vol. 165,  
No. 5.

(87) PCT Pub. No.: **WO2009/077993**

PCT Pub. Date: **Jun. 25, 2009**

Guerios, et al., "Nerve growth factor mediates peripheral mechanical  
hypersensitivity that accompanies experimental cystitis in mice,"  
*Neurosci. Lett.*, 2006, 193-197, vol. 392, No. 3.

(65) **Prior Publication Data**

US 2010/0260775 A1 Oct. 14, 2010

Jaggar, et al., "Inflammation of the rat urinary bladder is associated  
with a referred thermal hyperalgesia which is nerve growth factor  
dependent," *Br. J. Anaesth.*, 1999, 442-448, vol. 83, No. 3.

**Related U.S. Application Data**

(60) Provisional application No. 61/014,171, filed on Dec.  
17, 2007, provisional application No. 61/061,149,  
filed on Jun. 13, 2008.

Lipps, "Isolation of nerve growth factor (NGF) from human body  
fluids; saliva, serum and urine: comparison between cobra venom and  
cobra serum NGF," *J. Nat. Toxins*, 2000, 349-356, vol. 9, No. 4.  
Abstract.

(51) **Int. Cl.**

**A61K 39/395** (2006.01)  
**C07K 16/22** (2006.01)

Lowe, et al., "Increased nerve growth factor levels in the urinary  
bladder of women with idiopathic sensory urgency and interstitial  
cystitis," *British journal of urology*, 1997, 572-577, vol. 79, No. 4.  
Abstract.

(52) **U.S. Cl.**

USPC ..... **424/145.1**; 424/130.1; 424/133.1;  
424/141.1; 530/387.1; 530/387.3; 530/388.23

Marchand, et al., "Increased NGF and TrkA Expression in Bladder  
Biopsies from Interstitial Cystitis Patients," *Anesthesiology*  
Abstracts of Scientific Papers Annual Meeting, 2003, No. 2003, p.  
Abstract No. A-1011.

(58) **Field of Classification Search**

None  
See application file for complete search history.

Sato et al., "The Role of Urinary Bladder Nerve Growth Factor in  
Reconstruction of Micturition Function in Streptozotocin-Induced  
Diabetes and Physiological Polyuria," *Journal of Nihon University  
Medical Association*, 2002, 447-455, vol. 61, No. 12. Abstract.

(56) **References Cited**

(Continued)

U.S. PATENT DOCUMENTS

5,503,986	A	4/1996	Steers et al.
6,008,003	A	12/1999	Haak-Frendscho et al.
7,252,822	B2*	8/2007	Shelton et al. .... 424/145.1
2003/0096753	A1	5/2003	Robertson et al.
2003/0108597	A1	6/2003	Chancellor et al.
2004/0121959	A1	6/2004	Boone et al.
2004/0131615	A1	7/2004	Shelton et al.
2004/0219144	A1	11/2004	Shelton et al.
2005/0074821	A1	4/2005	Wild, Jr. et al.
2006/0147932	A1	7/2006	Davies et al.

FOREIGN PATENT DOCUMENTS

WO	WO 2004032870	4/2004
WO	WO 2004058184	7/2004
WO	WO 2006065234	6/2006
WO	WO 2006131951	12/2006

*Primary Examiner* — Christine J Saoud  
*Assistant Examiner* — Jon M Lockard  
(74) *Attorney, Agent, or Firm* — Pfizer Inc.

(57) **ABSTRACT**

The present invention relates to the use of an anti-NGF anti-  
body in the treatment or prevention of pain and/or a lower  
urinary tract symptom (LUTS) associated with interstitial  
cystitis and/or painful bladder syndrome and/or bladder pain  
syndrome.

**7 Claims, No Drawings**